【获批】华海药业大丰收，900万喜提两个畅销新品

米内网09-20

精彩内容9月19日华海药业发布公告称，公司的马来酸依那普利片以及子公司长兴制药的阿立哌唑口服溶液获批上市。截至目前，华海药业在上述两个项目分别投入了研发费用约194万元和761万元。今年以来，华海药业收获满满，已有18个新产品获批。表1：华海药业最新获批的产品来源：公司公告马来酸依那普利片用于治疗各期原发性高血压，肾血管性高血压，各级心力衰竭，预防症状性心衰，预防左心室功能不全病人冠状动脉缺血事件...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2468044615?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-20 16:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2468044615","market":"sh","top_or_hot":-1,"title":"【获批】华海药业大丰收，900万喜提两个畅销新品","media":"米内网","content":"<div>\n<p>精彩内容9月19日华海药业发布公告称，公司的马来酸依那普利片以及子公司长兴制药的阿立哌唑口服溶液获批上市。截至目前，华海药业在上述两个项目分别投入了研发费用约194万元和761万元。今年以来，华海药业收获满满，已有18个新产品获批。表1：华海药业最新获批的产品来源：公司公告马来酸依那普利片用于治疗各期原发性高血压，肾血管性高血压，各级心力衰竭，预防症状性心衰，预防左心室功能不全病人冠状动脉缺血事件...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409201629079f09b083&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【获批】华海药业大丰收，900万喜提两个畅销新品</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【获批】华海药业大丰收，900万喜提两个畅销新品\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-20 16:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409201629079f09b083&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容9月19日华海药业发布公告称，公司的马来酸依那普利片以及子公司长兴制药的阿立哌唑口服溶液获批上市。截至目前，华海药业在上述两个项目分别投入了研发费用约194万元和761万元。今年以来，华海药业收获满满，已有18个新产品获批。表1：华海药业最新获批的产品来源：公司公告马来酸依那普利片用于治疗各期原发性高血压，肾血管性高血压，各级心力衰竭，预防症状性心衰，预防左心室功能不全病人冠状动脉缺血事件...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409201629079f09b083&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409201629079f09b083&s=b","article_id":"2468044615","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409201629079f09b083&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2468044615","pubTimestamp":1726819572,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容9月19日华海药业发布公告称，公司的马来酸依那普利片以及子公司长兴制药的阿立哌唑口服溶液获批上市。截至目前，华海药业在上述两个项目分别投入了研发费用约194万元和761万元。今年以来，华海药业收获满满，已有18个新产品获批。在中国三大终端六大市场，阿立哌唑口服溶液的销售额呈现快速增长态势，2023年增幅达87.54%，销售额已超过5000万元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600521":"华海药业","BK0012":"证金概念","BK0239":"医药制造","BK0185":"二线龙头","BK0070":"员工持股","BK0188":"融资融券","BK0028":"国家队","BK0201":"可转债"},"translate_title":"[Approved] Huahai Pharmaceutical has a bumper harvest, 9 million to mention two best-selling new products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":1},"content_text":"精彩内容9月19日华海药业发布公告称，公司的马来酸依那普利片以及子公司长兴制药的阿立哌唑口服溶液获批上市。截至目前，华海药业在上述两个项目分别投入了研发费用约194万元和761万元。今年以来，华海药业收获满满，已有18个新产品获批。表1：华海药业最新获批的产品来源：公司公告马来酸依那普利片用于治疗各期原发性高血压，肾血管性高血压，各级心力衰竭，预防症状性心衰，预防左心室功能不全病人冠状动脉缺血事件。米内网数据显示，目前该产品的竞争格局（原研+国产）达15家。图1：2023年作用于肾素-血管紧张素系统的药物TOP10产品来源：米内网格局数据库在中国三大终端六大市场（统计范围见文末），马来酸依那普利片是作用于肾素-血管紧张素系统药物TOP10产品，2023年的销售规模超过了2.6亿元。近几年在国产品牌的持续进攻下，原研企业默沙东的市场份额跌至不到1%。阿立哌唑口服溶液用于治疗13～17岁青少年和成人的精神分裂症，目前该产品已有15家国内药企获得生产批文。图2：阿立哌唑口服溶液的销售情况（单位：万元）来源：米内网格局数据库2019年康弘药业拿下了阿立哌唑口服溶液的首仿+首家过评，随后越来越多国内药企加入市场争夺。在中国三大终端六大市场，阿立哌唑口服溶液的销售额呈现快速增长态势，2023年增幅达87.54%，销售额已超过5000万元。表2：华海药业今年以来获批的新产品（按批文日期统计）来源：米内网中国申报进度（MED）数据库","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468044615"}